Month: May 2020

EMERYVILLE, Calif., May 15, 2020 (GLOBE NEWSWIRE) — Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced the U.S. launch of Shine Forward with Dravet, a unique set of online tips, tools, and advice from Dravet families designed to inspire deeper connections between parents and siblings of children diagnosed with Dravet syndrome.Dravet syndrome is a rare childhood-onset epilepsy marked by frequent debilitating seizures, lifelong developmental and motor impairments, and an increased risk of sudden death. The severity and unpredictability of the disease, coupled with around-the-clock concern for the diagnosed child’s well-being, can present significant emotional and logistical challenges for all members of the family.“Families managing life with Dravet are incredibly strong...

CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will present preclinical data for XMT-1592, its Dolasynthen ADC candidate targeting NaPi2b, and its Immunosynthen STING-agonist ADC platform at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting being held from June 22 – June 24, 2020.   Details of the posters are as follows:Poster Title: XMT-1592, a Site-Specific Dolasynthen-Based NaPi2b-Targeted Antibody-Drug Conjugate for the Treatment of Ovarian Cancer and Lung AdenocarcinomaAbstract Number: 7067Poster Number: 2894Date: June 22, 2020Session Type: Poster...

HOUSTON, May 15, 2020 (GLOBE NEWSWIRE) — Sysco Corporation (NYSE:SYY) today announced that the Company will webcast its presentation of the 2020 Bernstein Strategic Decisions Conference on Friday, May 29, at 9:00 a.m. ET.The live webcast for the event can be accessed at investors.sysco.com. An archived replay of the webcast will be available shortly after the live event is completed.For purposes of public disclosure, including this and future similar events, Sysco uses the investor relations portion of its website as the primary channel for publishing key information to its investors, some of which may contain material and previously non-public information.About SyscoSysco is the global leader in selling, marketing and distributing food products to restaurants, healthcare and educational facilities, lodging establishments and other...

NEW YORK, May 15, 2020 (GLOBE NEWSWIRE) — Xcel Brands, Inc. (NASDAQ: XELB) (“Xcel” or the “Company”), a brand management and media company, today announced that it will report its first quarter 2020 financial results after the market closes on May 19, 2020. The Company will hold a conference call with the investment community at 5:00 p.m. Eastern Time that day.A webcast of the conference call will be available live on the Investor Relations section of Xcel’s website at https://www.xcelbrands.com/. Interested parties unable to access the conference call via the webcast may dial 855-327-6837. A replay of the conference call will be available on the Company website for approximately two weeks following the event and can be accessed at 844-512-2921 using replay pin number 10009675.About Xcel BrandsXcel Brands, Inc. (NASDAQ:XELB) is...

CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that the Company plans to present preclinical data supporting its lead artificial antigen-presenting cell (aAPC) program, RTX-321, for the potential treatment of human papillomavirus (HPV) 16-positive cancers, during the American Association for Cancer Research (AACR) Virtual Annual Meeting II. The meeting is being held from June 22-24, 2020, and all posters will be available online on the first day of the conference.“The risk of cancer is strongly associated with HPV infection, with the high-risk strain, HPV 16, accounting for approximately 70% of all cervical cancers and 80% of...

This is the convening notice for the extraordinary general meeting of shareholders of Brunel International N.V. (“Company”) that will take place on Monday 29 June 2020 at 2.00 p.m. CEST at the offices of the Company at John M. Keynesplein 33, 1066 EP Amsterdam.AGENDA: 1. Opening2. Appointment of Mr A.G. Maude as member of the Board of Directors (voting item)3. CloseThe voting rights can only be exercised by a proxy granted by electronic means. Proxy and voting instructions can be given from 2 June 2020 until 22 June 2020 at 5 p.m. CEST via www.abnamro.com/evoting. The intermediaries will need to issue a statement via www.abnamro.com/intermediary, no later than 23 June at 11 a.m. CEST stating that the shares were registered in the name of the holder thereof on the Record Date.Shareholders and others with meeting rights on the Record Date...

Dit is de oproeping voor de buitengewone algemene vergadering van aandeelhouders van Brunel International N.V. (“Vennootschap”) op maandag 29 juni 2020 om 14:00 uur ten kantore van de Vennootschap aan het John M. Keynesplein 33, 1066 EP Amsterdam.AGENDA:1. Opening2. Benoeming van de heer A.G. Maude tot lid van de raad van bestuur (ter beslissing)3. SluitingDe agenda met toelichting ligt ter inzage en is kosteloos verkrijgbaar bij Brunel International N.V., John M. Keynesplein 33, 1066 EP Amsterdam, en is opvraagbaar bij ABN AMRO Bank N.V. (“ABN AMRO”, e-mail: ava@nl.abnamro.com) en te raadplegen op de website van Brunel International N.V.: (www.brunelinternational.net).De registratiedatum voor de vergadering is 1 juni 2020, na verwerking van alle bij- en afschrijvingen per die datum (de “Registratiedatum”). VIRTUELE VERGADERINGAandeelhouders...

CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced two upcoming virtual poster presentations introducing the first preclinical data from the JTX-1811 program and data on the characterization of treatment emergent ICOS hi CD4 T cells with vopratelimab and their association with durable clinical responses. These posters will be presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting, being held June 22-24, 2020.Virtual Poster and Audio Presentation Details:Title: Preclinical evaluation of JTX-1811, an anti-CCR8 antibody with enhanced ADCC activity, for preferential depletion of tumor-infiltrating regulatory T cellsAuthor...

TORONTO, May 15, 2020 (GLOBE NEWSWIRE) — Pasinex Resources Limited (CSE: PSE) (FSE: PNX) (The “Company” or “Pasinex”) previously announced that due to logistics and delays caused by the COVID-19 pandemic, the Company was relying on the British Columbia Securities Commission’s (the “Commission”) blanket order BCI 51-515 to postpone the filing of its annual financial statements and management’s discussion and analysis (collectively, the “Annual Filings”) for the year ended December 31, 2019.In response to the COVID-19 pandemic, the Commission and other securities regulatory authorities in Canada have granted a blanket exemption allowing issuers an additional 45 days to complete their regulatory filings that were otherwise due during the period March 23, 2020 to June 1, 2020.The Company’s joint venture in Turkey continues to operate...